Recommendation of the President – Qalsody (tofersen)

On 14 May 2025,  the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 59/2025 on the appraisal of drug Qalsody (tofersen) under the new drug program “Treatment of patients with amyotrophic lateral sclerosis (ICD-10: G12.2)”

Publication in Public Information Bulletin (BIP) >>